Navigation Links
Controversial Study to Test Link Between Insomnia and Sleep Apnea
Date:2/9/2009

Measuring Prevalence of Sleep Apnea Among Insomnia Patients

ALBUQUERQUE, N.M., Feb. 9 /PRNewswire/ -- The Sleep and Human Health Institute (SHHI) was awarded a grant to study one of the most controversial aspects of Chronic Insomnia. Conventional wisdom connects insomnia to psychological factors -- stress, racing thoughts, and worries -- and is usually treated with sleeping pills or talk therapy. Pitted against the CW is the provocative theory that a large percentage of Chronic Insomniacs suffer from Obstructive Sleep Apnea (OSA), a physical breathing problem that might cause unwanted or unexpected sleeplessness.

Several leading sleep researchers have espoused this theory for the last decade; and Philips Respironics, a world leader in the treatment of obstructive sleep apnea, has awarded a $50,000 grant to co-sponsor the study in Albuquerque, NM to measure the occurrence of OSA in Chronic Insomnia patients.

"The Sleep and Human Health Institute has a history of groundbreaking work, and this study will be an important advancement in understanding the relationship between Insomnia and Sleep Apnea," said David P. White, M.D., Chief Medical Officer, Philips Respironics. "We know there are many skeptics who insist Chronic Insomnia is largely a psychological problem, but recent studies on certain patients have already shown that continuous positive airway pressure (CPAP) therapy or upper airway surgery significantly decreases insomnia."

Unlike other studies that investigated patients at sleep centers, the new research will examine randomly selected patients seeking care at their primary care clinics. This approach provides data much closer to what goes on in the general population compared to sleep center cohorts.

"This opportunity will clarify whether Sleep Apnea is a common problem often overlooked in Chronic Insomnia patients," declared Dr. Barry Krakow, principal in
'/>"/>

SOURCE Sleep and Human Health Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
2. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
3. New Study Shares Benchmarks for Fixed-Dose Combination (FDC) Drug Development
4. New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
7. New Study Provides Benchmarks for Winning Brand Team Management
8. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
9. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
10. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
11. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK,Iceland,November24/PRNewswire-FirstCall/--deCOD...hasreceivednoticefrom,theNasdaqStockMarketthattrad...vember30,2009andaForm25-NSEwillbefiledwiththe,Secu...scommonstock,fromlistingonNasdaq,unlessthecompanyf....Thecompanyhasfiledsuchanappeal,which,willstaythes...
(Date:11/24/2009)... Health care employment grew by 29,000...ne to show consistent growth during the U.S. reces...ain in trouble, and health systems are coming clos...stead of just administrators. , ...ployment continued growing in October despite the ...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.a...lowedthepatentapplicationfor,itsnano-particleorald...hlyefficientapproachtoincorporatepeptidesor,protei...ryofdrugs,otherwiseadministeredasinjections.NODtec...ymacromoleculardrugssuchasinsulin,interferon,grow...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyannounce...hasapprovedthe,investigationalnewdrugapplication(I...nsulinformulationtotreatdiabetes.ThisIND,approvala... , Diabetesisadisordercharacteristicofhighblo...etesoftenresultinseveremicro-and,macro-vasculardis...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2
...ollowing was issued,today by the Greater Baltimore...O, Greater Baltimore Committee, 140 company owner...rea,bioscience community, WHAT:, The third annua...N:, Tuesday, March 18, 2008, 8:00 a.m. / Breakfa...ram, WHERE:, Renaissance Harborplace Hotel, 202 ...
...rocess, Drive Value from Appraisals, OTTAWA, Marc...ng,provider of web-based employee performance and ... has been selected by Quiznos to provide a system,...adquarters. Quiznos is a,national chain with over ...usy consumers who are looking for a tasty, fresher...
...d Support of National Electronic Disease ...Calif., March 17 Computer,Sciences Corporation (N...ed a,task order from the Centers for Disease Contr... supporting the National Electronic Disease,Survei...m helps the CDC,manage and enhance public health s...
Other Biology Technology:Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Quiznos Selects Halogen for Fresh Approach to Talent Management 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:11/25/2009)... may be just as vital to your health as what you e...ological Studies. Their experiments in mice reveal...f genes in the liverthe body,s metabolic clearingh... the body,s circadian clock as conventional wisdom...vity of a large number of genes completely indepen...
(Date:11/24/2009)...and flabby arteries from collapsing have been true...re no longer needed -- once the arteries are stren...ors had no choice but to leave them in place. , ...partment of Biomedical Engineering has developed a...ugs where they,re needed, then dissolves. , "Our...
(Date:11/24/2009)...d is a matter of debate. A high-profile study a fe...ent of their carbon from trees and leaves, evidenc...d aquatic ecosystems. , But new research from th...y to be true. Algae provide a much richer diet for...h published this week in the Proceedings of the N...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 1AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 3DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 1DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8
...g bones, a healthy immune system, protection again...ere,s yet another item for the expanding list of v...n," keeps the heart, the body,s long-distance runn...gan pharmacologist Robert U. Simpson, Ph.D., think...er." , In studies in rats, Simpson and his team ...
...11, 2008 The J. David Gladstone Institutes today ..., MD, PhD, also of Kyoto University and UCSF, has ...ntributions in reprogramming adult skin cells to p...eive half of the $1 million award. Cloning pioneer...er half of the prize for their landmark generation...
...ational May Concern Law Enforcement Departments, ...ulletin Board: STIY), the leader in electro-stun t...sting law enforcement departments that,have purcha...ade their,weapons in for Stinger S-200 electronic ...ssions., Ron Bellistri, Stinger,s CEO, stated, "I...
Other Biology News:Vitamin D: New way to treat heart failure? 2Vitamin D: New way to treat heart failure? 3Gladstone's Shinya Yamanaka wins prestigious Shaw Prize 2Stinger Systems To Offer Taser Trade-In Program 2
Mouse Anti-Xanthine Oxidase Prediluted Monoclonal Antibody, Unconjugated, Clone SPM325 from Abcam
Mouse Anti-Vancomycin Monoclonal Antibody, Unconjugated, Clone 2G1 from Abcam
Mouse Anti-14-3-3 Binding Motif, phospho (Ser) Monoclonal Antibody, Unconjugated, Clone 4E2 from Cell Signaling Technology
Endotoxin Free Water from Mo Bio Laboratories, Inc.
Biology Products: